X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6142) 6142
Publication (432) 432
Book Review (78) 78
Newsletter (59) 59
Book Chapter (13) 13
Magazine Article (9) 9
Conference Proceeding (7) 7
Dissertation (5) 5
Newspaper Article (5) 5
Book / eBook (4) 4
Data Set (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4887) 4887
female (2972) 2972
male (2942) 2942
middle aged (2291) 2291
adult (2148) 2148
index medicus (1982) 1982
interleukin-2 (1851) 1851
oncology (1655) 1655
animals (1570) 1570
aged (1548) 1548
immunotherapy (1388) 1388
interleukin-2 - adverse effects (1378) 1378
immunology (1330) 1330
interleukin-2 - therapeutic use (1171) 1171
interleukin-2 - administration & dosage (1015) 1015
mice (955) 955
cancer (950) 950
treatment outcome (794) 794
therapy (701) 701
cytokines (659) 659
transplantation (596) 596
lymphocytes (572) 572
recombinant interleukin-2 (521) 521
care and treatment (514) 514
melanoma (503) 503
adolescent (475) 475
medicine, research & experimental (475) 475
t-lymphocytes - immunology (475) 475
t cells (472) 472
antineoplastic combined chemotherapy protocols - therapeutic use (471) 471
pharmacology & pharmacy (469) 469
hematology (458) 458
surgery (438) 438
expression (437) 437
carcinoma, renal cell - drug therapy (433) 433
kidney neoplasms - drug therapy (426) 426
antineoplastic agents - therapeutic use (416) 416
antibodies, monoclonal - therapeutic use (413) 413
health aspects (410) 410
melanoma - drug therapy (387) 387
research (384) 384
chemotherapy (379) 379
t-cells (366) 366
kidney neoplasms - therapy (365) 365
combined modality therapy (363) 363
interleukin-2 - immunology (357) 357
carcinoma, renal cell - therapy (348) 348
dose-response relationship, drug (342) 342
neoplasms - therapy (341) 341
metastatic melanoma (338) 338
interleukin-2 - metabolism (337) 337
antineoplastic combined chemotherapy protocols - adverse effects (334) 334
time factors (332) 332
drug administration schedule (328) 328
t-lymphocytes, regulatory - immunology (328) 328
interleukin-2 - pharmacology (322) 322
melanoma - therapy (322) 322
interferon-alpha (321) 321
antineoplastic agents - adverse effects (316) 316
kidney neoplasms - pathology (316) 316
il-2 (314) 314
killer cells, natural - immunology (314) 314
survival (313) 313
cells, cultured (311) 311
interleukin-2 - biosynthesis (300) 300
analysis (297) 297
recombinant proteins - therapeutic use (296) 296
aged, 80 and over (295) 295
neoplasm metastasis (291) 291
immunosuppressive agents - therapeutic use (289) 289
lymphocyte activation (284) 284
drug therapy (282) 282
flow cytometry (278) 278
recombinant proteins - adverse effects (277) 277
interleukins (275) 275
renal cell carcinoma (274) 274
interleukin-2 - blood (272) 272
mice, inbred c57bl (269) 269
cells (265) 265
child (265) 265
interleukin 2 (264) 264
regulatory t-cells (264) 264
interferon (257) 257
medicine & public health (256) 256
metastasis (255) 255
recombinant proteins (255) 255
activation (254) 254
interleukin-2 - genetics (254) 254
mice, inbred balb c (253) 253
drug therapy, combination (252) 252
interferon-alpha - administration & dosage (252) 252
survival analysis (252) 252
prognosis (249) 249
rats (249) 249
immunotherapy - methods (248) 248
in-vivo (247) 247
dendritic cells (246) 246
interferon-alpha - adverse effects (246) 246
survival rate (246) 246
high-dose interleukin-2 (240) 240
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5991) 5991
German (58) 58
Chinese (52) 52
French (41) 41
Japanese (31) 31
Spanish (17) 17
Russian (12) 12
Italian (11) 11
Polish (5) 5
Dutch (4) 4
Danish (3) 3
Swedish (2) 2
Hebrew (1) 1
Hungarian (1) 1
Norwegian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Urology, ISSN 0302-2838, 2016, Volume 71, Issue 3, pp. 426 - 436
Abstract Context While vascular endothelial growth factor-targeted therapy and mammalian target of rapamycin inhibition are effective strategies in treating... 
Urology | Papillary | Systematic review | Sunitinib | Non-clear cell renal cell carcinoma | Everolimus | Chromophobe | UROLOGY & NEPHROLOGY | PHASE-II | Niacinamide - analogs & derivatives | Anilides - therapeutic use | Bevacizumab - therapeutic use | Humans | Interleukin-2 - therapeutic use | Antineoplastic Agents - therapeutic use | Interferons - therapeutic use | Comparative Effectiveness Research | Quinolones - therapeutic use | Everolimus - therapeutic use | Imidazoles - therapeutic use | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Carcinoma, Renal Cell - pathology | Pyrrolidinones - therapeutic use | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Disease-Free Survival | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Indoles - therapeutic use | Kidney Neoplasms - pathology | Erlotinib Hydrochloride - therapeutic use | Quinolines - therapeutic use | Kidney Neoplasms - drug therapy | Indazoles - therapeutic use | Medical colleges | Care and treatment | Carcinoma, Renal cell | Endothelial growth factors | Analysis | Endothelium | Clinical Medicine | Urologi och njurmedicin | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin | Urology and Nephrology
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 11/2011, Volume 103, Issue 21, pp. 1572 - 1587
Unlike cytotoxic agents that indiscriminately affect rapidly dividing cells, newer antineoplastic agents such as targeted therapies and immunotherapies are... 
TYROSINE KINASE INHIBITORS | DENILEUKIN DIFTITOX | PHASE-II TRIAL | ONCOLOGY | SUNITINIB INDUCES HYPOTHYROIDISM | ALPHA-INTERFERON THERAPY | RECOMBINANT INTERLEUKIN-2 | HIGH-DOSE INTERLEUKIN-2 | THYROXINE-BINDING GLOBULIN | RENAL-CELL CARCINOMA | CHRONIC VIRAL-HEPATITIS | Hypothyroidism - chemically induced | Thyroid Function Tests | Hyperthyroidism - diagnosis | Interleukin-2 - adverse effects | Recombinant Fusion Proteins - adverse effects | Humans | Ipilimumab | Antibodies, Monoclonal - adverse effects | Antineoplastic Agents - administration & dosage | Recombinant Proteins - adverse effects | Tetrahydronaphthalenes - adverse effects | Hyperthyroidism - chemically induced | Thalidomide - analogs & derivatives | Antineoplastic Agents - adverse effects | Diphtheria Toxin - adverse effects | Thyroid Hormones - blood | Anticarcinogenic Agents - adverse effects | Interleukin-2 - analogs & derivatives | Thyroiditis, Autoimmune - chemically induced | Molecular Targeted Therapy - methods | Thyroid Gland - drug effects | Thalidomide - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Hyperthyroidism - blood | Radioimmunotherapy | Hypopituitarism - etiology | Hypothyroidism - diagnosis | Alemtuzumab | Hypothyroidism - etiology | Neoplasms - drug therapy | Iodine Radioisotopes - administration & dosage | Hypopituitarism - complications | Neoplasms - immunology | Hypothyroidism - drug therapy | Quality of Life | Interferon-alpha - adverse effects | Hypothyroidism - blood | Thyroid Gland - metabolism | Antibodies, Neoplasm - adverse effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Complications and side effects | Usage | Thyroid diseases | Diagnosis | Antineoplastic agents | Thyroid gland function tests | Risk factors | Index Medicus | Review
Journal Article
Brain, Behavior, and Immunity, ISSN 0889-1591, 2008, Volume 23, Issue 1, pp. 36 - 40
Abstract Chronic stress and depression are widely known to down-regulate the immune system, and several antidepressants can reverse this impairment, with or... 
Psychiatry | Allergy and Immunology | Antidepressant | Chronic stress | Cytokines | Fluoxetine | CD4/CD8 | Natural killer | Depression | B cells | T cells | PSYCHIATRY | PROLIFERATION | IMMUNOLOGY | NEUROSCIENCES | ANIMAL-MODELS | SEROTONIN | RECEPTORS | EXPRESSION | MODULATION | LYMPHOCYTES | Stress, Psychological - prevention & control | Tumor Necrosis Factor-alpha - genetics | Antidepressive Agents, Second-Generation - administration & dosage | Antidepressive Agents, Second-Generation - therapeutic use | CD4-Positive T-Lymphocytes - immunology | CD4-CD8 Ratio | Flow Cytometry | T-Lymphocytes - metabolism | T-Lymphocytes - drug effects | Restraint, Physical - methods | CD8-Positive T-Lymphocytes - metabolism | Killer Cells, Natural - immunology | Restraint, Physical - adverse effects | Female | Fluoxetine - therapeutic use | Interferon-gamma - genetics | B-Lymphocytes - metabolism | CD4-Positive T-Lymphocytes - metabolism | Reverse Transcriptase Polymerase Chain Reaction | B-Lymphocytes - drug effects | Interleukin-2 - genetics | Animals | B-Lymphocytes - immunology | CD8-Positive T-Lymphocytes - drug effects | Fluoxetine - administration & dosage | T-Lymphocytes - immunology | Cell Proliferation - drug effects | Killer Cells, Natural - drug effects | Mice | Mice, Inbred BALB C | Killer Cells, Natural - metabolism | CD8-Positive T-Lymphocytes - immunology | Chronic Disease | CD4-Positive T-Lymphocytes - drug effects | Stress, Psychological - etiology | Stress, Psychological - physiopathology | Complications and side effects | Depression, Mental | Biological response modifiers | Antidepressants, Tricyclic | Interferon gamma
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2014, Volume 32, Issue 33, pp. 3771 - 3778
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2007, Volume 8, Issue 11, pp. 975 - 984
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2012, Volume 18, Issue 7, pp. 2039 - 2047
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 26, pp. 2517 - 2526
Journal Article
Journal Article